Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025

SAN DIEGO, July 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from a new analysis using real-world data from CAHtalog®, a comprehensive registry of patients with classic congenital adrenal hyperplasia in the United States. The analysis demonstrated significant variability in glucocorticoid treatment regimens and frequent changes in health status and outcomes over time in both pediatric and adult patients. These results were presented at the Endocrine Society's ...